MD, PhD Albert E.G. Kr von dem Borne (Professor of Clinical Hematology and Immunohematology) , Claudia Folman (Doctorate Student) , Gabor E. Linthorst (Medical Student), MD Leendert Porcelijn (Head of the Laboratory of Platelet and Leukocyte Serology), Sonja van den Oudenrijn (Doctorate Student), MD, PhD Ellen van der Schoot (Head of the Immunocytology Laboratory), MD, PhD Masja de Haas (Senior Scientist)
{"title":"11血小板生成素:在血小板紊乱中的作用及作为临床新药的应用","authors":"MD, PhD Albert E.G. Kr von dem Borne (Professor of Clinical Hematology and Immunohematology) , Claudia Folman (Doctorate Student) , Gabor E. Linthorst (Medical Student), MD Leendert Porcelijn (Head of the Laboratory of Platelet and Leukocyte Serology), Sonja van den Oudenrijn (Doctorate Student), MD, PhD Ellen van der Schoot (Head of the Immunocytology Laboratory), MD, PhD Masja de Haas (Senior Scientist)","doi":"10.1016/S0950-3536(98)80059-0","DOIUrl":null,"url":null,"abstract":"<div><p>The cloning and characterization of thrombopoietin and its receptor Mpl in the past few years has been a major advance in haematology. It opens new ways of studying congenital and acquired platelet disorders, leading to new insights in the pathogenesis and treatment of this group of diseases.</p><p>The Tpo level of the blood appears to be a useful marker for the differentiation between thrombocytopenia due to peripheral destruction and that due to thrombocytopoietic failure. No simple clinical parameter exist for this important differential diagnostic problem.</p><p>When recombinant thrombopoietin becomes available for therapy it will rapidly become the drug of choice for many of our patients. However, because of all the legal and commercial issues at stake it is expected that it will still take a few more years before general availability is realized. Short peptides with Tpo activity (<span>Cwirla et al, 1997</span>; <span>Kimura et al, 1997</span>), which can be synthesized chemically, may form a more easily obtainable alternative.</p></div>","PeriodicalId":77029,"journal":{"name":"Bailliere's clinical haematology","volume":"11 2","pages":"Pages 427-445"},"PeriodicalIF":0.0000,"publicationDate":"1998-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0950-3536(98)80059-0","citationCount":"2","resultStr":"{\"title\":\"11 Thrombopoietin: its role in platelet disorders and as a new drug in clinical medicine\",\"authors\":\"MD, PhD Albert E.G. Kr von dem Borne (Professor of Clinical Hematology and Immunohematology) , Claudia Folman (Doctorate Student) , Gabor E. Linthorst (Medical Student), MD Leendert Porcelijn (Head of the Laboratory of Platelet and Leukocyte Serology), Sonja van den Oudenrijn (Doctorate Student), MD, PhD Ellen van der Schoot (Head of the Immunocytology Laboratory), MD, PhD Masja de Haas (Senior Scientist)\",\"doi\":\"10.1016/S0950-3536(98)80059-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The cloning and characterization of thrombopoietin and its receptor Mpl in the past few years has been a major advance in haematology. It opens new ways of studying congenital and acquired platelet disorders, leading to new insights in the pathogenesis and treatment of this group of diseases.</p><p>The Tpo level of the blood appears to be a useful marker for the differentiation between thrombocytopenia due to peripheral destruction and that due to thrombocytopoietic failure. No simple clinical parameter exist for this important differential diagnostic problem.</p><p>When recombinant thrombopoietin becomes available for therapy it will rapidly become the drug of choice for many of our patients. However, because of all the legal and commercial issues at stake it is expected that it will still take a few more years before general availability is realized. Short peptides with Tpo activity (<span>Cwirla et al, 1997</span>; <span>Kimura et al, 1997</span>), which can be synthesized chemically, may form a more easily obtainable alternative.</p></div>\",\"PeriodicalId\":77029,\"journal\":{\"name\":\"Bailliere's clinical haematology\",\"volume\":\"11 2\",\"pages\":\"Pages 427-445\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1998-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/S0950-3536(98)80059-0\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bailliere's clinical haematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0950353698800590\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bailliere's clinical haematology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0950353698800590","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
摘要
在过去的几年中，血小板生成素及其受体Mpl的克隆和表征是血液学的一个重大进展。它开辟了研究先天性和获得性血小板疾病的新途径，对这类疾病的发病机制和治疗有了新的认识。血液Tpo水平似乎是一个有用的标志，以区分血小板减少，由于外周破坏和由于血小板生成失败。对于这个重要的鉴别诊断问题，没有简单的临床参数存在。当重组血小板生成素可用于治疗时，它将迅速成为我们许多患者的首选药物。然而，由于所有的法律和商业问题的利害关系，预计它仍然需要几年的时间才能实现普遍可用性。具有Tpo活性的短肽(cirla et al, 1997;木村等人，1997)，它可以化学合成，可能形成一个更容易获得的替代品。
11 Thrombopoietin: its role in platelet disorders and as a new drug in clinical medicine
The cloning and characterization of thrombopoietin and its receptor Mpl in the past few years has been a major advance in haematology. It opens new ways of studying congenital and acquired platelet disorders, leading to new insights in the pathogenesis and treatment of this group of diseases.
The Tpo level of the blood appears to be a useful marker for the differentiation between thrombocytopenia due to peripheral destruction and that due to thrombocytopoietic failure. No simple clinical parameter exist for this important differential diagnostic problem.
When recombinant thrombopoietin becomes available for therapy it will rapidly become the drug of choice for many of our patients. However, because of all the legal and commercial issues at stake it is expected that it will still take a few more years before general availability is realized. Short peptides with Tpo activity (Cwirla et al, 1997; Kimura et al, 1997), which can be synthesized chemically, may form a more easily obtainable alternative.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
